Andy trained as a basic non-clinical scientist with undergraduate and postgraduate degrees in biochemistry and pharmacology from the University of Oxford, before undertaking postdoctoral studies at the University of Birmingham. Andy then followed a long-held ambition to apply scientific endeavor to the discovery of new medicines, by joining the pharmaceutical industry, initially with Novartis and subsequently GlaxoSmithKline. During nearly 15 years in the drug discovery industry Andy has led teams and pre-clinical discovery projects, successfully delivering multiple novel targets, clinical candidate drugs and early integrated clinical development plans. Andy has drug discovery experience across a wide range of therapeutic areas including rare diseases, respiratory and cardiovascular disease, oncology, and neurodegenerative disease

Andy is currently responsible for the translational science team at Mission Therapeutics and leveraging the company’s chemistry platform targeting de-ubiquitinating enzymes as novel treatments for a range of diseases, including Parkinson’s disease and neurodegeneration.